AKT1 and neoplasm: Again, based on multiplex assays of plasma and tumor material from additional rodent studies we discovered that [regorafenib + sildenafil] treatment caused a compensatory activation of AKT, with phosphorylation downstream of GSK3, which correlated with increased plasma levels of bFGF and PDGFbb.